Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose escalating trial of pegylated long-acting human growth hormone in adults with growth hormone deficiency
2008-001061-29Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2008
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in growth hormone deficiency (GHD) comparing NNC126-0083 dose-escalation arm with Placebo arm (2 arms). Primary endpoint: Safety and tolerability after four doses of NNC126-0083. Started Apr 2008; status: completed.
02
Drugs
somatropin pegol
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2008-001061-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001061-29.